United States Patent 8,746,242 (Medicament Dispenser) Scope and Claims: What the Patent Covers, How Broad It Is, and Where It Likely Sits in the US Patent Landscape
Executive summary. US Patent 8,746,242 claims a hand-actuated medicament dispenser with a movable mouthpiece cover that moves through three positions (covered → part-uncovered → uncovered) where only the final movement actuates dispensing. The independent claim is drafted at the level of an actuation logic gate tied to cover position and coupling to a dispensing mechanism. Dependent claims narrow into inhalation powder implementations, dual-active therapy architectures (bronchodilator + corticosteroid), multi-carrier layouts, and specific mechanical coupling via ratchet/drive gear with anti-return behavior and/or indexed release from blister-strip pockets.
What does US Patent 8,746,242 claim about the mouthpiece cover actuation logic?
What is the core independent claim limitation (Claim 1)
Claim 1 centers on a three-position cover that controls whether dispensing occurs:
- A medicament dispenser for use with a medicament carrier carrying multiple distinct medicament portions.
- The dispenser has:
- (a) a dispensing mechanism actuable to dispense the distinct portions.
- (b) a mouthpiece.
- (c) a cover that is movably mounted and moves sequentially:
- First position: mouthpiece covered
- Second position: mouthpiece part-uncovered
- Third position: mouthpiece uncovered
- Crucial control feature:
- Movement from first to second does not actuate dispensing.
- Further movement from second to third does actuate dispensing.
In functional terms, the claims require a mechanical/electromechanical interlock such that cover travel is an actuation trigger only after a defined threshold position.
How broad is Claim 1
Claim 1 is broad on several fronts:
- It is written as a generic “medicament dispenser” with a mouthpiece and cover interlock.
- It does not require a specific carrier type in Claim 1 (that appears in dependent claims).
- It does not require a specific active ingredient or therapy class in Claim 1.
- It does not require inhalation in Claim 1, though the dependent claim set strongly points to inhalers with powder carriers.
The scope is therefore strongest around the actuation gating concept: three-position cover movement with actuation only upon a specified step.
Claim construction pressure points
From a patentability and infringement perspective, the likely key interpretive issues are:
- Whether the “part-uncovered” state must correspond to a specific degree/functional change (the claim says “part-uncovered” but does not define the percent).
- What qualifies as “actuation of the dispensing mechanism.” Claim 1 requires that first-to-second movement does not result in actuation, but second-to-third does.
Those points matter because many competitors implement covers that both open airflow and mechanically drive dose mechanisms, making it easier for them to fall outside the “no actuation until third position” boundary.
What other features materially expand the claim scope beyond “cover gates actuation”? (Claims 2–8)
Claim 2: multiple carriers each with multiple distinct portions
Claim 2 adds:
- A plurality of medicament carriers.
- Each carrier carrying multiple distinct medicament dose portions.
This supports embodiments where multiple “dose sources” are staged and dispensed sequentially.
Claim 3: inhalation device, powdered portions, simultaneous inhalation
Claim 3 narrows into inhaler architecture:
- The dispenser is an inhalation device.
- Each dose portion is powder.
- The device enables user inhalation so the user inhales for simultaneous inhalation of the dose portions dispensed from the medicament carriers.
This implies:
- the dispensing mechanism must release dose portions in a way compatible with one inhalation event
- the mechanical actuation is coordinated with airflow path timing (even if airflow details are not explicitly recited in Claim 3)
Claim 4–5: bronchodilator + corticosteroid split between carriers
Claim 4 adds a specific two-carrier therapeutic split:
- First carrier: bronchodilator powder portions
- Second carrier: anti-inflammatory powder portions
Claim 5 specifies:
- bronchodilator = beta-agonist
- anti-inflammatory = corticosteroid
This is not a claim to a named drug, but it is a claim to drug-class combinations using carrier partitioning.
Claim 6: elongate medicament carrier
Claim 6 adds a structural carrier geometry limitation: the carrier is an elongate form.
Claim 7: receiving station + release + outlet + indexer
Claim 7 defines a modular dispensing mechanism:
- receiving station for each carrier
- a release that releases a distinct medicament portion on receipt
- an outlet communicating with the mouthpiece and the releasable portion
- an indexer to individually index distinct medicament portions
This expands the mechanical landscape from “cover actuation triggers something” to “cover actuation triggers a dose-indexing and release system.”
Claim 8: blister strip pockets with base/lid peel opening
Claim 8 narrows to a blister strip form carrier with:
- multiple distinct pockets spaced along length
- pockets defined between two peelable sheets
- release comprises a peeler engaging base sheet and lid sheet to peel open the pocket
This is one of the more concrete dependent claims that maps the patent into blister-based powder dose mechanics.
How does Claim 9–16 define cover coupling and ratchet actuation sequencing?
Cover coupling variations (Claims 9–12)
- Claim 9: cover couples directly with the dispensing mechanism.
- Claim 10: cover couples mechanically with the dispensing mechanism.
- Claim 11: housing defines an inlet for the mouthpiece such that inlet is:
- covered in first position,
- part-uncovered in second,
- fully revealed in third.
- Claim 12: housing contains the dispensing mechanism, cover is movably connected with housing.
These features support embodiments where the cover both:
- triggers dose dispensing only at a later position, and
- controls mouthpiece inlet exposure across the same three-position movement.
Rotational path movement (Claim 13)
Claim 13 requires cover movement on a rotational path. That is a design-limiting geometry.
Ratchet/gear sequencing and anti-return (Claims 14–16)
Claims 14–16 provide the mechanical interlock typical of the cover actuation threshold:
- Claim 14: cover interacts with a ratchet, ratchet interacts selectively with drive gear.
- Claim 15: on cover movement:
- first → second: ratchet disengaged from drive gear (no actuation)
- second → third: ratchet engaged with drive gear (actuation occurs)
- Claim 16: anti-return feature prevents return movement of drive gear on reverse cover travel (third → first).
This directly maps Claim 1’s “actuation only after second-to-third movement” into a ratchet engagement gating.
Which claims most directly capture mechanical interlocks (and how to read their breadth)? (Claims 17–30)
Unidirectional driving engagement features (Claims 17–18)
- Claim 17: ratchet and drive gear include first and second “ratchet features” providing unidirectional driving engagement.
- Claim 18: those ratchet features are disengaged except when the cover is positioned from the second position to the third position after moving toward third.
This is essentially a more granular version of Claim 15’s engagement gating, adding explicit unidirectional mechanics.
Cover connected to ratchet (Claim 19)
- Claim 19 says the cover is connected to the ratchet.
That connects cover motion more tightly to the engagement/disengagement logic.
Powder carrier and combined single-carrier therapy (Claims 20–22)
- Claim 20: carrier carries distinct powder medicament portions.
- Claim 21: single medicament carrier where each medicament portion comprises both:
- bronchodilator and anti-inflammatory
- Claim 22: bronchodilator = beta-agonist, anti-inflammatory = corticosteroid.
This is an alternative therapeutic architecture:
- Claim 4–5 is “split carriers”
- Claim 21–22 is “co-formulated or paired components within each portion on a single carrier”
Interface gating architecture (Claims 23–24 and ratchet interface in 25–30)
- Claim 23: coupling is adapted such that only movement second → third results in actuation.
- Claim 24: dispensing mechanism has:
- first part connected to cover (moves with cover)
- second part drivable by first part
- interface where first part can only drive second part when cover moves from second to third.
- Claim 25–30: interface is a ratchet arrangement with ratchet and drive gear and related feature limitations:
- Claim 25: interface formed by ratchet arrangement
- Claim 26–28: ratchet and drive gear and unidirectional features disengaged except in second-to-third
- Claim 29–30: interface includes first and second components with unidirectional driving engagement and cover connected to the first component
Net effect
The dependent claim set creates multiple claim paths to the same actuation concept:
- direct ratchet engagement/disengagement (Claims 14–19)
- interface gating logic (Claims 23–24) with ratchet implementation (Claims 25–30)
This strengthens the estate against design-arounds where a competitor uses equivalent “actuation threshold only after a certain cover position” logic but tries to change structural details.
What patent landscape does this imply for US filings covering dose-indexing inhalers with multi-stage covers?
The claims sit in a crowded technology area: multi-dose inhalers and powder delivery devices with blister or compartment carriers and mechanical indexing. In that landscape, patents typically cluster into:
- Dose carrier formats (blister pockets, elongate carriers, indexing strips)
- Dose release mechanisms (peeler, piercer, mechanical release, outlet synchronization)
- Actuation mechanisms (gear trains, ratchets, anti-return)
- User interface and sequencing (mouthpiece cover designs, airflow shutters)
- Therapeutic combination delivery (bronchodilator + corticosteroid, separate or co-loaded)
US 8,746,242’s differentiator is the three-position cover with an explicit non-actuation threshold from first to second position, coupled with ratchet/gear gating and, in some claims, inlet exposure timing across the same positions.
How strong is the patent estate for “actuation-threshold covers” in infringement and design-around terms?
Strength points
- The independent claim anchors on a clear, binary functional condition: first-to-second movement does not actuate; second-to-third movement actuates.
- Dependent claims tie that condition to widely recognizable hardware: ratchet/drive gear, anti-return, unidirectional ratchet features disengaged except at a specific cover interval.
- The estate provides alternative embodiments for therapy implementation (split carriers vs single carrier with combined components).
Design-around pathways likely to matter
Competitors seeking to avoid coverage could target one or more of these elements:
- remove the three-position cover sequence (e.g., only two cover states)
- make the first-to-second movement actuate some part of the dispensing mechanism (even partially), breaking the “does not result in actuation” condition
- decouple cover motion from mechanical coupling to the dispensing mechanism
- use an actuation system not tied to cover threshold positions (e.g., separate user trigger or continuous drive)
Because the patent is drafted around the cover’s controlled engagement with the dispensing mechanism, design-arounds that separate user cover movement from the dispensing actuation event are the most direct route.
Which claim features map to typical generic/competitive risk categories?
Generic entry risk
This is a device patent, not a chemical composition patent. Generic “entry” risks come from:
- copying the same mechanical dosing architecture
- copying the same multi-stage cover sequencing logic and ratchet gating
- copying carrier and blister peel release architectures where dependent claims are invoked
High-risk infringement scenarios
- multi-dose powder inhalers with a cover that sequentially opens the mouthpiece and only triggers the dose at the final open state
- mechanisms that implement a ratchet engagement window corresponding exactly to second-to-third cover movement
- blister-strip peeler implementations combined with the gating cover logic
Lower-risk scenarios
- inhalers with two-stage covers that both open airflow and trigger dosing without the explicit “no actuation” first-to-second interval
- designs where dosing is actuated by a separate button/slider independent of cover cover travel
- devices using electronic actuation synchronized to sensors rather than mechanical threshold gating by cover position (depending on how a court construes “movement of the cover…results in actuation”)
Claim-by-claim scope map (what each claim adds)
| Claim |
What it covers beyond Claim 1 |
| 1 |
Three-position cover: actuation only second→third; medicament dispenser for multi-portion carriers |
| 2 |
Multiple carriers, each with multiple distinct portions |
| 3 |
Inhalation device; powder portions; user inhalation enables simultaneous inhalation of dispensed portions |
| 4 |
Two carriers: bronchodilator portions on first; anti-inflammatory portions on second |
| 5 |
Bronchodilator = beta-agonist; anti-inflammatory = corticosteroid |
| 6 |
Carrier is elongate form |
| 7 |
Mechanism includes receiving station, release, outlet, indexer; individually indexes distinct portions |
| 8 |
Blister strip pockets with peelable base/lid; peeler opens a pocket |
| 9 |
Cover couples directly to dispensing mechanism |
| 10 |
Cover couples mechanically |
| 11 |
Housing inlet is covered/part-uncovered/revealed in the three cover positions |
| 12 |
Dispensing mechanism within housing; cover movably connected |
| 13 |
Cover moves on rotational path |
| 14 |
Cover interacts with ratchet; ratchet selectively interacts with drive gear |
| 15 |
Ratchet disengaged first→second; engaged second→third |
| 16 |
Anti-return prevents drive gear return on reverse cover movement |
| 17 |
Unidirectional ratchet features on ratchet and drive gear |
| 18 |
Ratchet features disengaged except during second→third window |
| 19 |
Cover connected to ratchet |
| 20 |
Carrier carries distinct powder portions |
| 21 |
Single carrier; each portion comprises bronchodilator + anti-inflammatory together |
| 22 |
Beta-agonist + corticosteroid in the combined portion |
| 23 |
Only second→third movement results in actuation (explicit restatement/strengthening) |
| 24 |
Two-part dispensing mechanism with interface that permits drive only in second→third; first part moves with cover |
| 25 |
Interface is formed by ratchet arrangement |
| 26 |
Ratchet arrangement includes ratchet and drive gear |
| 27 |
Unidirectional ratchet features on ratchet and drive gear |
| 28 |
Ratchet features disengaged except during second→third |
| 29 |
Ratchet arrangement has first and second components with unidirectional engagement |
| 30 |
Cover connected to first component |
Timing and exclusivity: how to treat expiration risk for US 8,746,242
No prosecution/filing dates, maintenance status, or term adjustments are provided here. Without those, a precise US expiration date or adjusted expiration cannot be stated from the claim text alone.
Key Takeaways
- US 8,746,242’s independent claim is anchored on an actuation threshold: cover movement from first to second position does not actuate; only second to third actuates.
- Dependent claims expand into inhalation powder implementations and bronchodilator (beta-agonist) + corticosteroid (anti-inflammatory) delivery using either split carriers or co-loaded portions within a single carrier.
- The strongest mechanical claim paths are the ratchet/drive gear gating and anti-return features, which translate the functional threshold into specific engagement/disengagement behavior.
- In infringement/design-around terms, the key variable is whether a product’s dose actuation is triggered only at a specific cover position transition. Separating cover movement from dose actuation is the most direct route to reducing risk.
FAQs
-
What elements of US 8,746,242 are most important to prove infringement?
The three-position cover sequence and the requirement that only second→third movement actuates the dispensing mechanism.
-
Do claims require that the mouthpiece inlet opens only at the third position?
Not in Claim 1, but the inlet covered/part-uncovered/revealed sequence is explicitly recited in Claim 11.
-
Is the patent limited to bronchodilator-corticosteroid therapy?
Not in Claim 1. The bronchodilator + corticosteroid combination is addressed in dependent claims (Claims 4–5 and 21–22).
-
What carrier types are covered in the claim set?
The independent claim is generic to “medicament carrier,” while dependent claims include elongate carriers (Claim 6) and blister strip pockets with peelable base/lid (Claim 8).
-
What mechanical feature is used to enforce the actuation threshold?
The dependent claims repeatedly use a ratchet and drive gear engagement window where engagement occurs only during second→third cover movement (Claims 14–18, 24–28).
References (APA)
No external sources were provided or cited in the prompt beyond the claim text for US Patent 8,746,242.
